Mutation detail:
| Mutation site | T86A |
| Virus | Varicella-Zoster virus |
Mutation level  |
Amino acid level |
| Gene/protein/region type | ORF36 |
| Gene ID | 1487667 |
| Country | - |
| Mutation type |
nonsynonymous mutation |
| Genotype/subtype/clade | - |
| Sample |
cell line |
| Variants | - |
| Viral reference sequence | AB097933.1 |
| Drug/antibody/vaccine | ACV-resistant, Cf1743-resistant |
| Transmissibility |
- |
| Transmission mechanism | - |
| Pathogenicity |
- |
| Pathogenicity mechanism | - |
| Immune escape mutation | - |
| Immune escape mechanism | - |
| RT-PCR primers probes | - |
Protein detail:
| Protein name | Thymidine Kinase |
| Uniprot protein ID | P09250 |
| Protein length | 341 amino acids |
| Protein description | Thymidine kinase catalyzes the transfer of the gamma-phospho group of ATP to thymidine to generate dTMP in the salvage pathway of pyrimidine synthesis. The dTMP serves as a substrate for DNA polymerase during viral DNA replication. Allows the virus to be reactivated and to grow in non-proliferative cells lacking a high concentration of phosphorylated nucleic acid precursors. |
Literature information:
| Pubmed ID | 22190713 |
| Clinical information | No |
| Disease | - |
| Published year | 2012 |
| Journal | JOURNAL OF VIROLOGY |
| Title | In Vitro-Selected Drug-Resistant Varicella-Zoster Virus Mutants in the Thymidine Kinase and DNA Polymerase Genes Yield Novel Phenotype-Genotype Associations and Highlight Differences between Antiherpesvirus Drugs |
| Author | G. Andrei,D. Topalis,P. Fiten,C. McGuigan,J. Balzarini |
| Evidence | Table 1 |